143 related articles for article (PubMed ID: 28104077)
1. Cost of Hospital Admissions in Medicare Patients With Atrial Fibrillation Taking Warfarin, Dabigatran, or Rivaroxaban.
Vaughan Sarrazin MS; Jones M; Mazur A; Cram P; Ayyagari P; Chrischilles E
J Am Coll Cardiol; 2017 Jan; 69(3):360-362. PubMed ID: 28104077
[No Abstract] [Full Text] [Related]
2. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL
J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051
[TBL] [Abstract][Full Text] [Related]
3. Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study.
Rome BN; Gagne JJ; Avorn J; Kesselheim AS
Am Heart J; 2021 Mar; 233():109-121. PubMed ID: 33358690
[TBL] [Abstract][Full Text] [Related]
4. Factors influencing dabigatran or warfarin medication persistence in patients with nonvalvular atrial fibrillation.
Annavarapu S; Gandhi PK; Li Y; Arora P; Moretz C; Wang C; Sander SD; Andrews GA
J Comp Eff Res; 2018 Jul; 7(7):685-691. PubMed ID: 29808717
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
[TBL] [Abstract][Full Text] [Related]
6. Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin.
Gilligan AM; Franchino-Elder J; Song X; Wang C; Henriques C; Sainski-Nguyen A; Wilson K; Smith DM; Sander S
Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):203-212. PubMed ID: 30251553
[TBL] [Abstract][Full Text] [Related]
7. [Not Available].
Oldgren J
Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512140
[No Abstract] [Full Text] [Related]
8. Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation.
Singh SM; Wijeysundera HC
Curr Cardiol Rep; 2015 Aug; 17(8):61. PubMed ID: 26081245
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
[TBL] [Abstract][Full Text] [Related]
10. Direct Oral Anticoagulants in Cardiac Amyloidosis-Associated Heart Failure and Atrial Fibrillation.
Mentias A; Alvarez P; Chaudhury P; Nakhla M; Moudgil R; Kanj M; Hanna M; Desai MY
Am J Cardiol; 2022 Feb; 164():141-143. PubMed ID: 34848050
[No Abstract] [Full Text] [Related]
11. Rivaroxaban versus warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation: A meta-analysis.
Phan K; Wang N; Pison L; Kumar N; Hitos K; Thomas SP
Int J Cardiol; 2015 Apr; 185():209-13. PubMed ID: 25797679
[No Abstract] [Full Text] [Related]
12. Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding.
Hospodar AR; Smith KJ; Zhang Y; Hernandez I
Am J Cardiovasc Drugs; 2018 Aug; 18(4):317-325. PubMed ID: 29740750
[TBL] [Abstract][Full Text] [Related]
13. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.
Graham DJ; Reichman ME; Wernecke M; Hsueh YH; Izem R; Southworth MR; Wei Y; Liao J; Goulding MR; Mott K; Chillarige Y; MaCurdy TE; Worrall C; Kelman JA
JAMA Intern Med; 2016 Nov; 176(11):1662-1671. PubMed ID: 27695821
[TBL] [Abstract][Full Text] [Related]
14. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease.
Lopes RD; Thomas L; Di Fusco M; Keshishian A; Luo X; Li X; Masseria C; Friend K; Mardekian J; Pan X; Yuce H; Jones WS
Am J Cardiol; 2021 Jun; 148():69-77. PubMed ID: 33667438
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation.
Mensch A; Stock S; Stollenwerk B; Müller D
Pharmacoeconomics; 2015 Mar; 33(3):271-83. PubMed ID: 25404426
[TBL] [Abstract][Full Text] [Related]
17. [Anticoagulation for patients with non-valvular atrial fibrillation].
Mizoguchi T; Yasaka M
Nihon Rinsho; 2016 Apr; 74(4):627-33. PubMed ID: 27333751
[TBL] [Abstract][Full Text] [Related]
18. All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin.
Gilligan AM; Gandhi P; Song X; Wang C; Henriques C; Sander S; Smith DM
Am J Cardiovasc Drugs; 2017 Dec; 17(6):481-492. PubMed ID: 28795348
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial.
Hohnloser SH; Cappato R; Ezekowitz MD; Evers T; Sahin K; Kirchhof P; Meng IL; van Eickels M; Camm AJ;
Europace; 2016 Feb; 18(2):184-90. PubMed ID: 26487668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]